Production (Stage)
SAB Biotherapeutics, Inc.
SABS
$1.81
$0.052.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 114.70K | -- | 263.10K | 944.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 114.70K | -- | 263.10K | 944.60K |
| Cost of Revenue | 7.66M | 7.65M | 7.83M | 6.82M | 8.15M |
| Gross Profit | -7.66M | -7.54M | -7.83M | -6.56M | -7.20M |
| SG&A Expenses | 3.11M | 2.47M | 3.48M | 3.64M | 4.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.77M | 10.12M | 11.31M | 10.46M | 12.34M |
| Operating Income | -10.77M | -10.01M | -11.31M | -10.20M | -11.39M |
| Income Before Tax | -5.20M | -11.39M | -10.35M | -7.34M | -5.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.20M | -11.39M | -10.35M | -7.34M | -5.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.20M | -11.39M | -10.35M | -7.34M | -5.03M |
| EBIT | -10.77M | -10.01M | -11.31M | -10.20M | -11.39M |
| EBITDA | -9.99M | -9.22M | -10.34M | -9.15M | -9.41M |
| EPS Basic | -0.56 | -1.23 | -1.12 | -0.79 | -0.54 |
| Normalized Basic EPS | -0.35 | -0.77 | -0.70 | -0.50 | -0.34 |
| EPS Diluted | -0.56 | -1.23 | -1.12 | -0.79 | -0.54 |
| Normalized Diluted EPS | -0.35 | -0.77 | -0.70 | -0.50 | -0.34 |
| Average Basic Shares Outstanding | 9.29M | 9.29M | 9.26M | 9.26M | 9.24M |
| Average Diluted Shares Outstanding | 9.29M | 9.29M | 9.26M | 9.26M | 9.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |